Pharmacists cannot engage in generic substitution
if a physician specifically notes otherwise, or if DPS laws exist that allow the patient to prevent the substitution through what is called "patient consent" actions as to the brand vs.
Canadian employers that use drug plan management strategies such as pay-direct cards, generic substitution
or dispensing fee caps can realize significantly lower health care costs.
Indian pharma considers the GCC a high growth market because the governments here are opting for increased generic substitution
, there is a large demographic with high purchasing power and an increase in the burden of lifestyle diseases,'[euro]oCi he said.
However, a focus on generic substitution
and price cuts will restrict the growth of the market.
Under many state statutes, there is no requirement for a pharmacist to seek physician approval prior to generic substitution
, unless it is plainly written into the prescription.
Prescription drug cost trend Cost sharing targets Generic substitution
Administrative fees Discounts Rebates
The main drivers for growth in this market are the launch of new AEDs, the continued uptake of recent AEDs, and the lower-than-average rate of generic substitution
in Spain compared with other countries, although this may change during the forecast period due to government cost-cutting strategies.
The Japanese Government has been highly receptive to generic substitution
They are trusted by the community to offer professional advice and therefore can either drive adherence to a certain drug brand or encourage a swap - which also might be driven by obligatory generic substitution
(aut idem) legislation," said Arno Sosna, Veeva's Director of Product Management, Europe.
Dr James Evans, a pharmaceutical industry analyst at visiongain, said: “The next few years are a potential bonanza for the generics industry, as a result of patent expiries, increased spending power in emerging national markets, governmental drives to increase generic substitution
in Japan, and the coming of biosimilars to pharma markets.
8 per cent in 2009, but a rising disease burden is likely to put pressure on the government to encourage greater generic substitution
, the report states.
Health Minister Mary Harney revealed a new system of generic substitution
and reference pricing - which could be law by next year - will cut the price of medical bills for patients and the state.